COSTA MESA, Calif., July 25, 2014 /PRNewswire-iReach/ -- Full Service CRO WCCT Global welcomes Peter Nieto as the new Vice President of Business Development. Peter has been in the pharmaceutical industry for over 30 years in a number of different business development positions with some of the largest CROs in the industry. These positions were primarily related to business development/sales management and marketing. The experience he has obtained over the past 30 years makes him a key and strategic asset to WCCT Global as they continue to expand as an emerging leader in the full service CRO arena. Key areas of continued growth for WCCT Global are late stage research, influenza challenge clinical trials, and patient recruitment solutions in many therapeutic areas.
WCCT Global's VP of Global Clinical Development, Lee Barsky, stated, "The wealth of strategic knowledge Peter brings to the management of our business growth and expansion of our service offerings is unparalleled. Our organization will continue to be a leader and trend setter in clinical innovation; paving the pathway to the biopharmaceutical industry." Peter will be attending a number of upcoming industry events where many sponsor partners will be able to discuss their early and late stage clinical development needs and receive more insight on the capabilities WCCT Global can offer them to save time and money regarding their clinical programs.
More about WCCT Global:
WCCT Global is a multi-site, full-service global contract research organization (CRO) of outsourced early and late phase drug development services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, "With compassion for people, we strive for tomorrow's therapies to be available today" truly exemplifies the focus and reason for our cutting-edge work, both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
To request information about how WCCT Global can be of benefit your next clinical research program, CLICK HERE
Media Contact: Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE WCCT Global